|
Oct 10
|
Provectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference Call
|
|
Jun 13
|
Provectus Biopharmaceuticals Announces Investor Webinar for 2024 Annual Meeting of Stockholders
|
|
May 21
|
Provectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting
|
|
Dec 18
|
Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodium for Use as Anticancer and Antiviral Vaccine Adjuvant
|
|
Jun 28
|
Provectus Biopharmaceuticals Establishes Research Collaboration with University of Tennessee College of Veterinary Medicine to Investigate Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal Sodium for Canine Soft Tissue Sarcomas
|
|
Jun 26
|
Provectus Biopharmaceuticals Announces Stockholder Approval to Undertake Reverse Split of Outstanding Equities and Reduce Number of Authorized Equities by Same Ratio
|